CreativeOne Wealth LLC Cuts Stock Position in Insulet Corporation $PODD

CreativeOne Wealth LLC lessened its stake in shares of Insulet Corporation (NASDAQ:PODD) by 3.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,343 shares of the medical instruments supplier’s stock after selling 189 shares during the period. CreativeOne Wealth LLC’s holdings in Insulet were worth $1,679,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in PODD. Evelyn Partners Investment Management Services Ltd increased its holdings in shares of Insulet by 28.7% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 39 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Insulet by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock valued at $634,000 after purchasing an additional 45 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its stake in Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after purchasing an additional 48 shares in the last quarter. Mather Group LLC. raised its holdings in Insulet by 4.4% in the second quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock worth $360,000 after buying an additional 48 shares during the last quarter. Finally, Brooklyn Investment Group raised its holdings in Insulet by 7.0% in the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock worth $209,000 after buying an additional 52 shares during the last quarter.

Insider Buying and Selling at Insulet

In related news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Insulet Trading Down 0.6%

Shares of NASDAQ:PODD opened at $326.80 on Thursday. The stock’s 50-day simple moving average is $322.19 and its two-hundred day simple moving average is $316.21. The stock has a market capitalization of $22.99 billion, a price-to-earnings ratio of 99.33, a PEG ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s quarterly revenue was up 29.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Barclays raised their price target on shares of Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Truist Financial lifted their target price on Insulet from $390.00 to $412.00 and gave the stock a “buy” rating in a report on Friday, November 21st. Wells Fargo & Company upped their price target on Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Rothschild & Co Redburn lifted their price objective on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Finally, Wolfe Research upped their target price on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $379.65.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.